Abarelix
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Bedaquiline
Anti-tuberculosis agent (diarylquinoline ATP synthase inhibitor) · Antitubercular drug
Also known as Sirturo
START
400 mg OD ×2 wk, then 200 mg 3×/week with food
TYPICAL MAX
400 mg/day (loading phase)
STOP IF
QTc >500 ms, significant arrhythmia, or hepatotoxicity
WATCH
ECG/QTc, electrolytes, LFTs at baseline and periodically
CDSCO approvedSchedule H1ATC J04AK05
KDIGO 2024 + manufacturer label
- ONSET
- 2.5h · absorption
- PEAK
- 5h · Tmax (fed)
- t½
- 23.6w · t½ ~5.5 mo
- DURATION
- 2.3d · 3×/week
EXCRETION
Mainly faecal; minimal renal
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Limited data; use within an optimised MDR-TB regimen if benefit outweighs risk.
FDA category + note
Top interactionssee all 12 →
- AbarelixSevereDatabaseDDInter
- AbirateroneSevereDatabaseDDInter
- AdenosineSevereDatabaseDDInter
- AlfuzosinSevereDatabaseDDInter
Available in India
1 branded formulation. Look up specific brands in the Drugs workspace.
Mechanism
Inhibits mycobacterial ATP synthase (proton pump c-subunit), depleting ATP and producing bactericidal/sterilising activity against Mycobacterium tuberculosis including drug-resistant strains.
Indications
Multidrug-resistant pulmonary tuberculosis (combination regimen)
Dosing
- Adult
- 400 mg PO once daily for 2 weeks, then 200 mg three times weekly for 22 weeks, with food, in a combination regimen.
- Pediatric
- Weight-banded dosing under specialist care.
- Renal adjustment
- No adjustment in mild–moderate; caution in severe (limited data).
- Hepatic adjustment
- Caution; avoid in severe hepatic impairment.
- Geriatric
- Limited data; monitor ECG/LFTs.
- Max dose
- 400 mg/day (loading); 200 mg three times weekly (maintenance)
Pharmacokinetics
Onset
Antimycobacterial effect over weeks
Peak effect
~5 h (Tmax, with food)
Duration
Long (very prolonged terminal elimination)
Half-life
Terminal ~5.5 months (tissue redistribution)
Bioavailability
Increased ~2× with food
Protein binding
>99.9%
Metabolism
Hepatic CYP3A4 (N-desmethyl active metabolite)
Excretion
Mainly faecal; minimal renal
Contraindications
- Concomitant strong CYP3A4 inducers/inhibitors (caution)
- Hypersensitivity
- Caution: QT prolongation, hepatic disease
Side effects
Common
NauseaArthralgiaHeadacheQT prolongationTransaminase elevation
Serious
- QT prolongation / arrhythmia
- Hepatotoxicity
- Increased mortality signal (early trial — use within optimised regimen)
- Pancreatitis (rare)
Pregnancy & lactation
Pregnancy
Limited data; use within an optimised MDR-TB regimen if benefit outweighs risk.
Lactation
Accumulates in milk (animal data); weigh benefit/risk.
Drug interactions
Abiraterone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Adenosine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alfuzosin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alimemazine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amiodarone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amisulpride
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amitriptyline
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amoxapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Apomorphine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Ask House about Bedaquiline
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e, Katzung, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20